

Index

- acetazolamide, 47
 achromatopsia in dreams, 125
 adaptive standardized LORETA/FOCUSS (ALF), 75
 adenosine, 188
 adenosine deaminase gene, 169
 adenosine metabolism
 effects of caffeine, 408
 age
 risk factor for OSA, 258
 aging
 changes in sleep architecture, 269
 AIDS dementia
 brain SPECT imaging, 47
 airway study modalities, 256
 akathisia, 311
 alerting medication effects, 406
 amphetamine functional imaging, 407
 atomoxetine functional imaging, 408
 caffeine functional imaging, 408
 cholinergic stimulation imaging, 408–409
 default mode network and stimulant drugs, 407–408
 disorders of excessive sleepiness, 410–411
 mechanisms of brain function improvement, 411
 modafinil functional imaging, 409–410
 nicotine functional imaging, 408
 pharmacological MRI (phMRI), 406
 alpha gigantocellular nuclei (GiA), 11
 alpha-synucleinopathies, 51
¹²³I-MIBG uptake as diagnostic tool, 337
 Alzheimer's disease, 45, 187, 378
 and inflammation, 269
 apolipoprotein ε4 genotype risk factor, 270
 brain SPECT imaging, 47
 changes in sleep architecture, 269
 light and melatonin therapy, 177
 ¹²³I-MIBG findings, 335
 risk factors, 269–270
 with vascular dementia, 47
 American Academy of Sleep Medicine (AASM) sleep scoring rules, 72
 amphetamine
 functional imaging, 407
 neural effects in narcolepsy, 228
 amygdala, 172, 173, 175
 activation during REM sleep, 124
 amyloid beta plaque formation, 264
 Anger, Hal, 41
 angiography. *See* MRA (magnetic resonance angiography)
 angular momentum, 16
 annexin V protein, 49
 apolipoprotein ε4 genotype
 Alzheimer's disease risk factor, 270
 effects of OSD hypoxia, 270
 apoptosis
 brain SPECT imaging, 49
 arachnoid cyst imaging, 352–353
 armodafinil, 232, 410–411
 arousal
 basic arousal networks, 197–199
 hierarchical arousal network in the CNS, 197
 arterial spin labeling (ASL) techniques, 130
 ascending reticular activating system, 8, 209
 atomoxetine
 functional neuroimaging of effects, 408
 attention
 and vigilance, 137
 components of, 137
 role in information processing, 137
 attention and sleep deprivation
 distractor suppression, 138
 effects on preparatory attention, 141
 effects on selective attention, 137–138
 lapses from loss of top-down control, 140–141
 peripheral perceptual processing capacity, 139–140
 reduced functional circuits, 141–142
 sleep deprivation studies, 137
 sleeping when awake, 141–142
 attention-deficit hyperactivity disorder (ADHD), 407–408
 atypical parkinsonian syndromes
 and idiopathic RBD, 60
¹²³I-MIBG findings, 335
 augmentation problem
 RLS treatments, 363
 autonomic dysfunction
 assessment using ¹²³I-MIBG scintigraphy, 333
 changes caused by OSA, 281–282
 autonomic failure
 and ¹²³I-MIBG uptake, 336
 in synucleinopathies, 336
 autonomic functions
 changes caused by OSA, 275
 autonomic nervous system
 effects of *PHOX2B* gene defects, 293
 axonal imaging
 DTI of white matter tracts, 24–26
 B₀ (static magnetic field), 16
 Backus–Gilbert method, 75
 basal forebrain, 8
 basic arousal network, 197–199
 Bayesian minimum norm, 78–79
 Beck Depression Inventory (BDI), 221, 234
 behavior
 effects of sleep deprivation, 132
 influence of sleep on, 1
 behavioral studies
 effects of sleep deprivation on decision-making, 146
 benign epilepsy with centrotemporal spikes (BECTS), 384, 385, 386, 387
 benzodiazepine action
 role of GABA_A receptors, 397
 benzodiazepines, 396
 effects during sleep, 399–400
 effects during wakefulness, 397–399
 bicuculline, 8, 11
 biological clock, 3
 Biot–Savart Law, 65
 blood–brain barrier (BBB)
 disruption
 brain SPECT imaging, 48
 blood oxygen level-dependent imaging. *See* BOLD imaging
 blood pressure
 effects of OSA, 265
 body position and OSA risk, 259
 BOLD (blood oxygen level-dependent) activation signal in fMRI, 22–24
 BOLD (blood oxygen level-dependent) imaging
 sleep deprivation studies, 129–130
 BOLD (blood oxygen level-dependent) signal maps, 82
 boundary element method (BEM), 75
 brain cooling
 insomnia treatment, 202–204
 brain cystic lesions
 imaging, 352–353
 brain death assessment
 brain SPECT imaging, 48
 brain-derived neurotrophic factor (BDNF)
 link between brain health and sleep, 270
 link between cognition and sleep, 270
 brain electrophysiological integrity
 effects of sleep disorders, 270
 brain function
 temporal changes, 1
 brain functional organization
 effects of light exposure, 175
 brain glucose metabolism in narcolepsy, 223–225
 brain health
 effects of OSA-related secondary hypertension, 265
 effects of sleep deprivation, 264
 effects of sleep fragmentation, 264
 effects of sleep hypoxia, 264–265
 effects of sleep pathology, 264–265
 gene expression during sleep, 265

- brain imaging
 advanced MRI techniques, 22
 technical developments, 1
- brain metabolism
 relationship with functional connectivity, 111–112
- brain metabolite imaging
 MRS (magnetic resonance spectroscopy), 26–28
- brain molecular mechanisms
 and the function of sleep, 265
- brain parenchyma sonography (BPS). *See* transcranial B-mode sonography (TCS)
- brain perfusion in narcolepsy, 223–225
- brain plasticity
 and sleep, 3
 during REM sleep, 116–118
- brain structure and function
 in sleep apnea syndromes, 265–269
 mechanisms of pathological sleep effects, 269–270
- brain tumors
 brain SPECT imaging, 48
- brainstem, 8, 9, 173
 basic arousal network, 197–199
- brainstem lesions. *See* parasomnia overlap disorder case study
- brainstem raphe nuclei, 57
- breathing disorders
 sleep-related, 4–5
- breathing drive loss in sleep
 congenital central hypoventilation syndrome (CCHS), 293
- caffeine
 functional neuroimaging of effects, 408
- carbachol, 9
- carbamazepine, 301
- carbon 11 (¹¹C) labeled radiotracers, 32
- carbon 13 (¹³C) MRS, 26
- cardiac ¹²³I-MIBG uptake
 clinical significance, 337
 effects in neurodegenerative disorders, 333
 mechanism of reduced ¹²³I-MIBG uptake, 336–337
- cardiovascular disease
 and sleep disordered breathing, 5
- cataplexy, 4, 218, 224, 226, 408
 pharmacological treatments, 228
- cataplexy case study
 case history, 246
 discussion, 246–247
 imaging findings, 246
 imaging techniques, 246
- key results from
 neuroimaging, 247
 polysomnographic findings, 246
- catathrenia (sleep-related groaning), 304
- caudate nucleus, 58
- central autonomic network
 changes caused by OSA, 275
- cerebral vasculitis
 brain SPECT imaging, 48
- cerebrovascular disease
 diaschisis, 46
 SPECT imaging, 45–46
- chemically selective saturation (CHESS)
- choline, 28
 MRS visibility, 28
- cholinergic neurons, 8
- cholinergic stimulation
 neuroimaging, 408–409
- cholinergic system
 in multiple system atrophy, 308
 in Parkinson's disease, 308
 neuroimaging, 308
- chronobiology, 3
- chronotypes
 effects of sleep deprivation, 134
 link to *PERIOD3* (*PER3*) polymorphisms, 165–167
 time-of-day modulations in cognitive performance, 164–165
- cingulate cortex
 role in sleepwalking, 348
- cingulum bundle
 volume reduction in OSA, 250–251
- circadian clock
 suprachiasmatic nuclei (SCN), 187
- circadian processes
 brain mechanisms involved in sleep homeostatic interactions, 168
 interaction with sleep homeostatic processes, 168–169
 master clock, 163
 role of the suprachiasmatic nuclei (SCN), 163
 wake maintenance zone, 163
- circadian rhythm disorders
 and insomnia, 4
- circadian rhythms
 and the sleep/wake cycle, 163–164
 effects of light on sleep regulation, 174
 effects of misalignment, 3
 effects of sleep deprivation, 134
 influence of light exposure, 171
 neuroimaging, 3
 temporal changes in brain function, 1
- Clinical Global Impression of Change (CGI-C), 231
- clock gene *PERIOD3* (*PER3*). *See* *PERIOD3* (*PER3*) genotypes
- clonazepam, 302, 303, 349
- cocaine, 407
- cognitive aging effects
 similarity to sleep deprivation effects, 134, 154–155
- cognitive behavioral therapy
 for insomnia, 396
- cognitive brain responses
 time-of-day variations in *PERIOD3* (*PER3*) genotypes, 165–167
- cognitive decline
 and inflammation, 269
 and metabolic dysfunction, 269–270
- cognitive deficits
 congenital central hypoventilation syndrome (CCHS), 295–296
- cognitive function
 effects of OSA, 269–270
 vulnerability to sleep deprivation effects, 165–167
- cognitive neuroscience, 1
- cognitive performance
 time-of-day modulations in chronotypes, 164–165
- cognitive processes
 and the sleep/wake cycle, 163–164
- combined EEG and fMRI
 analysis strategies, 86–87
 artifact reduction methods, 85–86
 EMG recordings, 84
 findings in wakeful state, 93
 materials, 84
 methodology, 82–86
 motivation for combined recording during sleep, 82
 pulse artifact reduction, 86
 raw data quality, 85
 role in sleep disorder studies, 87
 scanner-generated imaging artifact reduction, 86
 signal transduction chain, 82–84
 sleep deprivation studies, 130
 sources of artifacts, 84
 subject comfort, 85
 subject safety issues, 85
- combined EEG and TMS, 125
- combined TMS and fMRI
 sleep deprivation studies, 130
- compensatory models
 decision-making under risk, 145
- computed tomography. *See* CT
- confusional arousals, 304
- congenital central hypoventilation syndrome (CCHS)
 causes, 293
 deficits in neurotransmitter systems, 297
 distribution of neural injury, 297
 effects of paired-like homeobox 2B (*PHOX2B*) gene defects, 293
 failure of CO₂ regulation, 295
 failure of O₂ regulation, 295
 features of, 293
 fMRI responses to ventilatory and autonomic challenges, 298
 injury related to CO₂ regulation, 295
 injury related to cognitive deficits, 295–296
 injury related to memory deficits, 295–296
 injury related to O₂ regulation, 295
 injury to neurotransmitter mediator sites, 297
 loss of affective influence on breathing, 296–297
 loss of breathing drive in sleep, 293
 loss of temperature influence on breathing, 296–297
 MRI tools for assessment, 293–294
 neuroimaging insights into the nature of brain injury, 298–299
 sparing of motor areas, 297
 structural injury underlying autonomic deficits, 294–295
- continuous positive airway pressure (CPAP), 5
 OSA treatment, 259
- contrast agents
 CT, 15
 gadolinium-based (MRI), 19
 MRI, 15
 properties of MRI contrast agents, 15–16
- coronary heart disease
 and sleep disordered breathing, 5
- creatine
 MRS visibility, 28
- Creutzfeldt–Jakob disease (CJD), 380
- CT (computed tomography), 1
 combination with PET, 31
 combined with SPECT, 51–52
 comparison with MRI, 15
 contrast agents, 15
 generation of contrast, 15
 use of X-rays, 15

Index

- CURRY software, 75
 cyclotrons
 production of
 radiopharmaceuticals,
 31–32
- Dale method, 74
 decision-making, 132
 and sleep deprivation, 145
 effects of sleep deprivation on
 monetary valuation,
 148–149
 effects of sleep deprivation on
 social valuation, 148–149
 effects of sleep deprivation, 132
 decision-making under risk
 and sleep deprivation, 145
 behavioral studies of sleep
 deprivation effects, 146
 compensatory models, 145
 effects of sleep deprivation,
 146–148, 149–150
 expectation-based models, 145
 heuristic strategies, 145
 models, 145–146
 neuroeconomic models,
 145–146
 neuroeconomics, 145
 default mode network (DMN),
 92, 105–106
 and stimulant drugs, 407–408
 effects of nicotine, 408
 effects of sleep deprivation, 130
 influence on sleep-deprived
 performance, 157
- dementia
 and idiopathic RBD, 60
 brain SPECT imaging, 47
 sleep apnea risk factor, 264
 dementia of Alzheimer's type
 brain SPECT imaging, 47
 dementia with Lewy bodies
 cardiac uptake of ¹²³I-MIBG,
 333
¹²³I-MIBG findings, 335
 depression, 199
 alterations in EEG sleep
 studies, 209
 level of disability caused by,
 209
 NREM sleep imaging studies,
 211–213
 potential insights from sleep
 neuroscience, 209
 REM sleep imaging studies,
 210–211
 sleep deprivation, 213
 depression/anxiety
 influence on brain structure in
 OSA, 251
 depressive disorders
 raphe hypoechogenicity, 59
 transcranial B-mode
 sonography (TCS), 59
 diabetes, 62
- and brain changes in OSA, 252
 and sleep disorders, 269–270
 risk factor for cognitive
 decline, 269–270
 diamagnetism, 15
 diaschisis
 SPECT imaging, 46
 diazepam, 396
 See also benzodiazepines.
 dipoles
 alignment in a magnetic
 field, 15
 disorders of arousal
 associated with NREM sleep,
 301–302
 associated with REM
 sleep, 302
 limitations of imaging
 modalities, 304
 neuroimaging of underlying
 pathology, 301
 nocturnal painful erections,
 302
 parasomnia overlap syndrome
 with RBD and
 sleepwalking, 302
 sleep terrors, 301–302
 sleepwalking, 301
 See also parasomnias.
 disorders of excessive sleepiness,
 411
 effects of alerting medication,
 410–411
 distractor suppression
 effects of sleep deprivation, 138
 dominantly inherited
 olivopontocerebellar
 atrophy, 379
 donepezil, 409
 effects in sleep deprivation
 studies, 132
 dopamine neuroimaging
 in idiopathic RBD, 326–329
 dopamine system, 363
 functional neuroimaging in
 RLS, 364–369
 in multiple system atrophy,
 306–308
 in Parkinson's disease,
 306–308
 involvement in restless legs
 syndrome, 355, 356, 363
 neuroimaging, 306–308
 dopamine transporter (DAT),
 363
 dopaminergic therapy
 for restless legs syndrome, 355
 dorsal anterior cingulate cortex,
 147
 dorsal raphe nucleus, 8
 dorsolateral prefrontal cortex,
 148, 173, 175, 199
 dorsomedial hypothalamus, 172,
 173, 175
 DQB1*0602 gene, 169
- dream correlates, 116
 REM sleep neuroimaging,
 115–116
 dream experience
 and brain structure, 125
 dream recall
 neural determinants, 125
 dream reports
 achromatopsia, 125
 as indicators of sleep health,
 125
 classification of contents,
 123–124
 distinct affective and cognitive
 dimensions, 124
 frightening content, 124
 macropsia, 125
 methods to collect reliable
 dream data, 123
 micropsia, 125
 misidentification for faces,
 124–125
 misidentification for places,
 125
 palinopsia, 125
 phenomenology of dreaming,
 123
 polyopia, 125
 statistical approach, 123–124
 visual aspects of dreams, 124
 visual distortions, 124–125
 dream research
 amygdala activation and
 dream content, 124
 dream content and
 information processing, 121
 dream reports, 121
 future directions, 126
 interpreting sleep
 neuroimaging data,
 121–123
 methodologies, 121
 neuropsychology of dream
 bizarreness, 124–125
 dreaming
 background neural activity, 125
 dreams
 memory content of, 116
 memory processing in, 116
 relationship to REM sleep
 neuroimaging, 118–119
 underlying neural
 mechanisms, 119
 drug-induced parkinsonism, 49
 DSM-IV-TR
 diagnostic criteria for PTSD,
 340
 DTI (diffusion tensor imaging),
 22, 24–26
 FACT algorithm, 25–26
 OSA treatment effects, 291
- electroencephalogram (EEG)
 AASM sleep scoring rules, 72
 and magnetoencephalography,
 62, 63–65
 application of LORETA to
 sleep data, 76–79
 channels used for recording
 sleep data, 72–73
 contribution to sleep research, 1
 effects of depression in sleep
 studies, 209
 features of vigilance states, 8
 findings in wakefulness, 91–92
 inverse problem, 65, 73–76
 inverse problem solutions, 79
 method used for analyzing
 sleep data, 72–73
 methods of solving the inverse
 problem, 73–76
 Rechtschaffen and Kales
 method, 72
 reference electrode
 problem, 73
 scoring rules for sleep
 activity, 72
 simultaneous EEG and fMRI
 in wakeful state, 93
 treatment of artifacts, 73
 See also combined EEG and
 fMRI.
 electroencephalogram (EEG), 125
 combined with TMS, 125
 electromyogram (EMG)
 features of vigilance states, 8
 with combined EEG and
 fMRI, 84
 electro-oculogram (EOG)
 features of vigilance states, 8
 eLORETA (exact low-resolution
 brain electromagnetic
 tomography), 75
 emotional neural systems
 relation to sleep states, 213
 emotional processing
 effects of sleep deprivation, 132
 encephalopathy related to
 electrical status epilepticus
 during sleep (ESES), 384,
 385, 386
 enuresis
 sleep-related, 302
 epilepsy, 45
 brain SPECT imaging, 47–48
 sleep-related, 352–353
 See also sleep-related
 epilepsies.
 epilepsy surgery
 use of magnetoence
 phalography, 65–66
 Epworth Sleepiness Scale (ESS),
 221, 231
 eszopiclone, 198–199, 396
 effects in insomnia, 401
 See also z-drugs.
 exact low-resolution brain
 electromagnetic tomography
 (eLORETA), 75

- excessive daytime sleepiness (EDS), 305
 in multiple system atrophy, 309–310
 in Parkinson's disease, 309–310
- expectation-based models
 decision-making under risk, 145
- expected utility model
 decision-making under risk, 145
- expiratory loading
 OSA neuroimaging, 277–278
- exploding head syndrome, 303
- external stimulation
 response in NREM sleep, 99–102
- ¹⁸F-FDG, 21
 PET imaging protocols, 37–38
 production process, 32
- FACT algorithm for DTI, 25–26
- fatal familial insomnia
 autonomic studies, 376
 [¹¹C] Flumazenil PET imaging, 381
 [¹¹C]-PK11195 PET imaging, 379
 characteristics, 375
 clinical features, 375–376
 EEG findings, 376
¹⁸F-FDG PET imaging, 378
 genetic features, 375–376
 hereditary prion disease, 375
 hormonal findings, 376
 MRS, 381–382
 MRI studies, 381–382
 neuroimaging, 377–382
 neuropathology, 376–377
 polysomnography, 376
 role of the limbic thalamus, 375
 sporadic cases, 376
- ferromagnetism, 16
- finite element method (FEM), 76
- FLAIR image (MRI), 18
- flip angle (MRI), 16
- flumazenil, 397
- fMRI (functional MRI), 1–2, 22
 applications, 22
 arterial spin labeling (ASL) techniques, 130
 BOLD activation signal, 22–24
 findings in wakefulness, 91, 92
 functional connectivity
 analysis, 105–106
 measurement of neuronal activity, 22–24
 simultaneous EEG and fMRI in wakeful state, 93
 use in functional brain mapping, 22
See also combined EEG and fMRI.
- focal brain lesions, 8
- focal underdetermined system solution (FOCUSS), 75
- forebrain, 8
- forehead cold pressor challenge
 OSA neuroimaging, 275
- Fourier transform methods, 20
- free radicals, 269
- Frégoli syndrome, 124
- frontal cerebral hypothermia
 potential treatment for insomnia, 202–204
- frontal lobe
 insomnia neuroimaging studies, 188, 190–193
- frontal lobe dementia (FD)
 brain SPECT imaging, 47
- frontopolar cortex, 173
- frontotemporal dementia, 378
 brain SPECT imaging, 47
- functional connectivity in the brain
 changes during sleep, 125
 default mode network (DMN), 105–106
 definition of functional connectivity, 105
 during NREM sleep phasic events, 110–111
 hierarchy of the low-frequency network, 107–110
 large-scale functional network throughout sleep, 106–107
 networks of spontaneous fluctuations, 105–106
 networks of spontaneous fluctuations in sleep, 106
 relationship with brain metabolism, 111–112
 resting state networks, 105–106
 spontaneous BOLD signal fluctuations, 105
- functional neuroimaging
 advantages of magnetoencephalography, 62
 techniques, 1–2
- fusiform face area (FFA), 139
- GABA (gamma-aminobutyric acid), 8
 MRS visibility, 28
- GABA_A receptor modulators, 396
- GABA_A receptors, 8
 role in action of benzodiazepines and z-drugs, 397
 targeting by sedative hypnotics, 396–397
- GABAergic neurons, 8–9
- gabapentin, 355
- gadolinium-based contrast agents, 15–16, 19
- gamma cameras, 41
- gender differences
 OSA risk, 258
- gene–environment interactions
 imaging in sleep disorders, 270
- gene expression during sleep, 265
- genetic factors
 restless legs syndrome, 356
- genetic risk factors for OSA, 259
- genioglossus advancement, 260
- genome-wide association studies
 restless legs syndrome, 356
- Gerstmann–Sträussler–Scheinker syndrome (GSS), 380
- glutamate
 MRS visibility, 28
- groaning
 sleep related (catathrenia), 304
- hallucinations, 4
 sleep related, 303
- Hamilton Anxiety Rating Scale (HAM-A) insomnia item, 192
- head trauma
 brain SPECT imaging, 48
- headaches
 sleep related (hypnic headaches), 303
- heart failure
 and sleep disordered breathing, 5
- heuristic strategies
 decision-making under risk, 145
- hierarchical arousal network in the CNS, 197
- hippocampal neurogenesis
 effects of OSA, 270
- hippocampus, 173
 volume reduction in OSA, 250
- hippocampus-dependent memory, 179–180
- histamine, 308
- histaminergic neurons, 8
- Huntington's disease, 378, 379
- hydrogen
 nuclear magnetic resonance, 15
 nucleus (proton) behavior in a magnetic field, 15
- hyoid advancement, 260
- hyperarousal in insomnia, 188
- hypersomnia, recurrent. *See* Kleine–Levin syndrome
- hypersomnias, 4
- hypertension
 and sleep disordered breathing, 5
 OSA risk factor, 265
- hypnagogic hallucinations, 218
- hypnic headaches, 303
- hypocretin, 308
 role in multiple system atrophy, 309
 role in narcolepsy, 218, 224
- hypocretin neurons, 209, 218
- hypocretin system, 305
- hypocretin systems in the tuberal hypothalamus, 8
- hypocretin-1 (Hcrt-1), 4
- hypocretin-2 (Hcrt-2), 4
- hypoglycemia, 408
- hypothalamic orexin system
 role in wake/sleep transitions, 91
- hypothalamus, 173, 175
 basic arousal network, 197–199
 dysfunction in narcolepsy, 224
 response to light in SAD, 176–177
- ¹²³I-MIBG scintigraphy
 assessment of autonomic dysfunction, 333
 cardiac uptake of ¹²³I-MIBG, 333
 clinical significance of cardiac MIBG uptake, 337
 findings in Alzheimer's disease, 335
 findings in atypical parkinsonian syndromes, 335
 findings in DLB, 335
 findings in idiopathic RBD, 335–336
 findings in multiple system atrophy, 335
 findings in Parkinson's disease, 334
 findings in progressive supranuclear palsy (PSP), 335
 findings in pure autonomic failure (PAF), 335
 findings in REM sleep behavior disorder (RBD), 333
 findings in tauopathies, 335
 mechanism of reduced ¹²³I-MIBG uptake, 336–337
 technique, 333–334
 use in neurodegenerative disorder diagnosis, 333
- ¹²³I-MIBG uptake, 336
 and autonomic failure, 336
 and RBD, 336
 clinical significance of cardiac uptake, 337
 diagnostic tool for alpha-synucleinopathies, 337
 in synucleinopathies, 336
 mechanism of reduced cardiac uptake, 336–337
- idiopathic RBD
 and neurodegenerative disorders, 59–60
 as indicator of neurodegenerative disease, 316
 clinical significance, 317–318

Index

- idiopathic RBD neuroimaging, 318
- brain metabolism studies, 323–324
- brain perfusion studies, 323–324
- diffusion tensor imaging (DTI), 322–323
- dopamine neuroimaging, 326–329
- findings, 329
- ¹²³I-MIBG findings, 335–336
- midbrain hyperchogenicity, 325–326
- MRI and CT, 318–319
- MRI-based volumetric measurement, 321–322
- premotor stage of Parkinson's disease, 324–325
- proton magnetic resonance spectroscopy (¹H-MRS), 319–321
- SPECT imaging, 51
- substantia nigra
- hyperchogenicity, 60, 325–326
- transcranial sonography (TCS), 325–326
- voxel-based morphometry, 322
- imaging
- technical developments, 1
- imaging genomics, 133
- inflammation
- and cognitive decline, 269
 - effects of sleep deprivation, 269
- information processing
- role of attention, 137
- insomnia, 5
- and circadian rhythm disorders, 4
 - and sleep regulatory mechanisms, 187–188
 - and the circadian clock, 187
- basic arousal networks, 197–199
- clinical symptoms, 197
- cognitive behavioral therapy, 396
- comorbidity, 187
- consequences for brain structure and function, 188
- definition, 197
- diagnostic criteria, 187
- economic burden in the U S A, 197
- frontal lobe neuroimaging studies, 188, 190–193
- functional neuroimaging approaches, 188
- hierarchical arousal network, 197
- hyperarousal state, 188
- impact on society, 187
- in older people, 187
- insomnia phenotypes, 193–194
- modulators of arousal, 199–200
- parietal lobe neuroimaging studies, 188, 193
- possible causal mechanisms, 187–188
- prevalence, 187, 197, 396
- public health problem, 197
- risk factor for health problems, 187
- risk factors, 197
- role of limbic and paralimbic hyperarousal, 199–200
- role of the neocortex, 200–202
- role of the thalamus, 200–202
- scarcity of neuroimaging studies, 187
- search for neural correlates, 187–188
- sleep homeostatic mechanism, 187–188
- structural neuroimaging approaches, 188
- subtypes, 193–194
- symptoms, 396
- temporal lobe neuroimaging studies, 188–190
- insomnia treatments
- frontal cerebral hypothermia, 202–204
- inspiratory loading
- OSA neuroimaging, 278–279
- insula, 173
- insular cortex, 147
- insulin resistance
- and sleep disorders, 269–270
 - and sleep fragmentation, 264
- inter-individual differences
- functional imaging of sleep deprivation responses, 155
 - imaging predictor of sleep deprivation response, 155–157
 - marker for response to sleep deprivation, 157
 - sleep deprivation responses, 154
- intraparietal sulcus (IPS), 138, 141, 173, 175, 193
- intrinsically photosensitive retinal ganglion cells (ipRGCs), 171–172, 177
- inversion recovery technique (MRI), 18–19
- iron
- neuroimaging in RLS, 371
- iron deficiency
- and restless legs syndrome, 356, 363
- iron metabolism
- and restless legs syndrome, 5
- jet lag, 177
- Kleine–Levin syndrome
- characteristic features, 240
 - possible etiologies, 240
 - possible genetic component, 240
 - recurrent episodes of hypersomnia, 240
- Kleine–Levin syndrome neuroimaging
- biochemistry, 242–243
 - brain perfusion, 240–241
 - cognitive function, 242
 - findings, 243
 - future directions, 243–244
 - morphology, 240
 - neuroimaging methods, 240
 - SPECT imaging, 51
- kuru, 380
- labetalol, 334
- Larmor equation, 16
- lateral habenula, 172
- lateral hypothalamus, 172
- laterodorsal tegmental cholinergic nuclei, 209
- learning, 118
- and REM sleep neural activity, 116–118
- lentiform nucleus, 58
- levetiracetam, 353
- levodopa, 355
- Lewy body dementia, 47
- brain SPECT imaging, 47
- light exposure, 171
- brain mechanisms involved in effects, 175–176
 - effects on brain functional organization, 175
 - effects on subsequent sleep, 177
 - hypothalamic response and psychiatric status, 176–177
 - influence on circadian rhythms, 171
 - influence on sleep homeostatic and circadian interactions, 174
 - influence on sleep/wake regulation, 171
 - intrinsically photosensitive retinal ganglion cells (ipRGCs), 171–172
 - modulators of brain responses, 173–174
 - non-image-forming functions, 171–172
 - PER3* genotype-dependent effects on sleep, 174–175
 - seasonal affective disorder (SAD), 176–177
 - sensitivity to blue light, 171–172
 - wavelength-dependent modulation of brain responses, 173
 - widespread influence on brain functions, 172–173
- light therapy
- range of potential applications, 177
- limbic system
- modulation of arousal, 199–200
 - role in wake/sleep transitions, 91
- limbic thalamus
- role in fatal familial insomnia, 375
- linkage studies, 356
- restless legs syndrome, 356
- local autoregressive average (LAURA), 75, 78–79
- locus coeruleus, 8, 164, 172, 175
- lorazepam. *See* benzodiazepines
- LORETA (low-resolution brain electromagnetic tomography), 1–2, 410
- application to EEG sleep data, 76–79
 - functional neuroimaging of therapeutic effects, 232
 - methodology, 73–76
 - See also* narcolepsy EEG tomography (LORETA).
- LORETA studies in narcolepsy
- ERP studies of modafinil effects, 235–237
- LORETA study of modafinil in narcolepsy
- brain regions linked to psychometric performance, 233–234
- M₀ (net magnetization vector, NMV), 16
- Machado–Joseph disease, 301
- macropsia in dreams, 125
- magnesium valproate, 353
- magnetic properties of materials, 15
- diamagnetism, 15
 - ferromagnetism, 16
 - paramagnetism, 15–16
 - superparamagnetism, 16
- magnetic resonance imaging, 1. *See* MRI
- magnetic resonance spectroscopy. *See* MRS
- magnetoencephalography, 1–2
- advantages in functional neuroimaging, 62
 - and EEG, 62, 63–65
 - basic principles, 63–65
 - clinical example (epilepsy surgery), 65–66
 - description, 62
 - development of the technology, 63
 - direct measure of brain electrophysiology, 62
 - inverse problem, 65

- point-contact SQUID, 63
 potential research and clinical applications, 62–63
 practical limitations, 62
 temporal resolution, 62
 theoretical limitations, 62
 use in sleep research, 66–70
- mammillary bodies
 volume reduction in OSA, 250
- maxillary-mandibular advancement, 260
- Maxwell's equations, 65
- MCH (melanin concentrating hormone) neurons
 role in control of REM sleep, 12
- medial prefrontal cortex, 92
- medications
 functional neuroimaging of effects, 5–6
- melanopsin ipRGCs, 171–172, 177
- melatonin, 163, 171, 177, 349, 350, 399
 sedating effects, 399
- memory
 and sleep, 3
 aspects of the relationship with sleep, 179
 declarative memory, 179
 dual declarative memory systems, 179–180
 effects of light exposure, 173
 visual short-term memory, 140
- memory consolidation
 hippocampus-dependent memory, 179–180
 neuroimaging investigations, 179–180
 processes happening during sleep, 185
 reactivation during sleep, 180–182
 reorganization during sleep, 182–184
 reprocessing during sleep, 184–185
 studies of link with sleep, 179
 systems memory consolidation, 179–180
- memory content of dreams, 116
- memory deficits
 congenital central hypoventilation syndrome (CCHS), 295–296
- memory processing
 in dreams, 116
 in REM sleep, 116–118
- metabolic function
 effects of sleep disorders, 269–270
- metabolic syndrome
 and sleep disorders, 269–270
 and sleep fragmentation, 264
- meta-iodobenzylguanidine (^{123}I -MIBG), 333
- methylphenidate, 407–408
- neural effects in narcolepsy treatment, 228
- micropsia in dreams, 125
- midazolam, 396
See also benzodiazepines.
- midbrain hyperchogenicity, 325–326
- mild cognitive impairment
 brain SPECT imaging, 47
- minimum norm estimates (MNE), 75
- mirtazapine, 399
- modafinil, 228
 effect on subjective sleepiness in narcolepsy, 236–237
 effects in narcolepsy, 231–232
 effects in sleep deprivation studies, 132
 effects on cognitive ERP latencies in narcolepsy, 236
 functional neuroimaging, 409–410
 increase in subcortical and cortical monoaminergic neurotransmission, 231
 neural effects in narcolepsy, 228–229
 neural effects of long-term treatment for narcolepsy, 229–230
 target regions in narcolepsy, 237
- modafinil in narcolepsy
 brain regions linked to psychometric performance, 233–234
 ERP studies with LORETA, 235–237
 mode of action, 233
- modafinil targets in narcolepsy, 233
 EEG tomography (LORETA) findings, 232–233
- monetary valuation
 effects of sleep deprivation, 148–149
- MP-RAGE images, 19
- MRA (magnetic resonance angiography), 20–21
- MRI (magnetic resonance imaging), 1
 additional contrast, 18–19
 advanced techniques for brain imaging, 22
 applications, 15
 combination with PET, 31
 comparison with CT, 15
 contrast agent properties, 15–16
 contrast agents, 15, 19
 detection of the MRI signal, 16
 diamagnetic materials, 15
 ferromagnetic materials, 16
 FLAIR image, 18
 flip angle, 16
- gadolinium-based contrast agents, 15–16, 19
 generation of contrast, 15
 image contrast (T1, T2, T2*), 19
 inversion recovery technique, 18–19
 measuring image quality, 20
 multislice versus volumetric imaging, 20
 net magnetization vector (NMV, M_0), 16
 noise (signal of no interest), 19–20
 nuclear magnetic resonance, 15
 paramagnetic materials, 15–16
 properties of materials used with, 15–16
 pulsed gradient magnetic fields, 15
 radio frequency fields, 15
 relaxation, 16–17
 signal of interest, 19–20
 signal of no interest (noise), 19–20
 signal-to-noise ratio (SNR), 20
 spatial resolution, 20
 spin density (proton density), 18
 spin echo, 17–18
 STIR image, 18
 strength of the magnetic fields, 15
 superparamagnetic materials, 16
 T1 and T2 relaxation, 17
 T2* relaxation, 17
 3-dimensional (3D) imaging, 20
 2-dimensional (2D) imaging, 20
 use of hydrogen nucleus magnetic resonance, 15
 voxels, 20
- MRS (magnetic resonance spectroscopy), 22
 carbon 13 (^{13}C) MRS, 26
 choline visibility, 28
 creatine visibility, 28
 during CPAP for OSA, 291
 GABA visibility, 28
 glutamate visibility, 28
 hydrogen (^1H) MRS, 26–28
 metabolite identification and quantification, 26–28
 multivoxel techniques, 27
N-acetylaspartate (NAA) visibility, 28
 oxygen 17 (^{17}O) MRS, 26
 phosphorus 31 (^{31}P) MRS, 26
 single-voxel MRS, 26
 spatial location techniques, 26–27
- MRV (magnetic resonance venography). *See* MRA (magnetic resonance angiography)
- (magnetic resonance angiography)
- multi-infarct dementia
 brain SPECT imaging, 47
- Multiple Sleep Latency Test (MSLT), 231
- multiple system atrophy, 49
 ataxic type, 379
 classification, 305
 clinical features, 305
 dopamine system dysfunction, 306–308
 excessive daytime sleepiness (EDS), 309–310
 extrapyramidal/autonomic type, 379
 future role of neuroimaging, 313
 imaging of dopamine function, 306–308
 imaging of the cholinergic system, 308
 incidence of sleep disorders, 305
 ^{123}I -MIBG findings, 335
 neuroimaging of chemical pathways, 305–309
 neuroimaging of sleep disorders, 305
 noradrenergic system imaging, 308–309
 OSA (obstructive sleep apnea), 310
 pathological processes, 305
 periodic limb movement syndrome, 310
 quality of life (QOL) rating scales, 305
 REM sleep behavior disorder (RBD), 311–313
 restless legs syndrome, 310
 role of hypocretin, 309
 serotonergic system imaging, 309
 sleep disordered breathing, 310
 sleep rating scales, 305
- Multiple Wakefulness Test (MWT), 231
- multislice imaging
 MRI, 20
- N*-acetyl aspartyl glutamate (NAAG), 28
- N*-acetylaspartate (NAA)
 MRS visibility, 28
- naloxone, 363
- narcolepsy, 4, 5, 408
 characteristic features, 218
 effects of modafinil, 231–232
 ERP studies of modafinil effects, 235–237
 hypothalamic dysfunction, 224
 modafinil effects on psychometric performance, 233–234

Index

- narcolepsy (cont.)
 neuroanatomy of wakefulness
 and cognition, 231
 pattern of cognitive
 dysfunction, 231
 role of hypocretin, 218, 224
 SPECT imaging, 50–51
 narcolepsy EEG tomography
 (LORETA)
 aims of the study, 232
 methods and findings, 232–233
 modafinil mode of action, 233
 targets for modafinil, 232–233
 narcolepsy functional
 neuroimaging
 brain glucose metabolism,
 223–225
 brain perfusion, 223–225
 neural correlates of emotional
 processing, 225
 neural correlates of reward
 processing, 225–226
 neurotransmission in
 narcolepsy, 223
 summary of findings, 226
 techniques, 223
 use of PET imaging, 223
 use of SPECT imaging, 223
 narcolepsy structural
 neuroimaging
 analysis of cortical thickness,
 220–221
 future developments, 221
 MRI visual inspection, 218
 MRS studies, 220
 voxel-based morphometry
 (VBM), 218–220
 narcolepsy treatment
 development of neuroimaging
 studies, 230
 neural effects of amphetamine,
 228
 neural effects of long-term
 modafinil, 229–230
 neural effects of
 methylphenidate, 228
 neural effects of modafinil,
 228–229
 pharmacological treatments,
 228
 narcolepsy treatment response
 neuroimaging study methods,
 228
 near-infrared spectroscopy (NIRS)
 during CPAP for OSA
 (obstructive sleep apnea),
 290–291
 neocortex
 role in insomnia, 200–202
 net magnetization vector (NMV,
 M_0), 16
 network model
 REM sleep onset and
 control, 12
 neurodegenerative disorders
 and idiopathic RBD, 59–60
 neuroeconomics, 145
 neuroimaging
 early applications to sleep/
 wake function, 2–3
 potential contributions to
 clinical sleep medicine,
 270–271
 potential contributions to OSA
 treatment, 270–271
 temporal changes in brain
 function, 1
 neuroimaging of sleep disorders
 future directions, 6
 neuroimaging technology
 sleep research applications,
 1–2
 neuropsychology of dream
 bizarreness, 124–125
 neurotransmission in narcolepsy,
 223
 nicotine
 functional neuroimaging of
 effects, 408
 nigrostriatal system
 degeneration in Parkinson's
 disease, 305
 nocturnal eating syndrome, 303
 nocturnal frontal lobe epilepsy
 (NFLE), 352–353, 384
 nocturnal painful erections, 302
 nocturnal seizures. *See* sleep-
 related epilepsies
 nocturnal wanderings case study
 arachnoid cyst imaging
 finding, 352
 case history, 352
 discussion and key points,
 352–353
 imaging findings, 352
 imaging technique, 352
 polysomnographic findings,
 352
 noise (signal of no interest), 19–20
 non-rapid eye movement sleep.
See NREM sleep
 noradrenergic neurons, 8
 noradrenergic system
 in multiple system atrophy,
 308–309
 in Parkinson's disease,
 308–309
 neuroimaging, 308–309
 norepinephrine, 164
 NREM sleep
 features of, 8
 functional neuroimaging
 studies, 210
 imaging studies in depression,
 211–213
 mechanisms involved, 8–9
 neural systems related to, 210
 neural underpinnings, 1
 preclinical evidence of neural
 mechanisms, 209
 relation to emotional neural
 systems, 213
 restoration of prefrontal cortex
 function, 210
 switch from waking state to, 9
 switching mechanisms, 8
 NREM sleep imaging
 compared with wakefulness, 96
 detailed functional
 neuroanatomy, 102–103
 functional connectivity during
 phasic events, 110–111
 neural correlates of sleep
 spindles, 97–99
 neural correlates of slow
 waves, 99
 neural events within NREM
 sleep, 96
 phasic activities, 96–97
 phasic activities and response
 to external stimulation,
 99–102
 sleep microarchitecture, 96
 sleep rhythms, 96–97
 sleep spindles, 96–97
 slow waves, 96–97
 nuclear magnetic resonance, 15
 nuclear medicine, 41
 nucleus accumbens, 147
 obesity
 risk factor for OSA, 258
 obsessive behavior, 199
 obstructive sleep apnea. *See* OSA
 (obstructive sleep apnea)
 olivary pretectal nucleus, 172
 opiate system
 involvement in restless legs
 syndrome, 363
 opioid system
 neuroimaging studies in RLS,
 369–371
 orexin neurons, 172
 orexin system, 305
 role in wake/sleep transitions, 91
 orexin systems in the tuberal
 hypothalamus, 8
 orexin-A, 4
 orexin-B, 4
 OSA (obstructive sleep apnea),
 4–5
 age risk factor, 258
 and inflammation, 269
 autonomic dysfunction caused
 by, 275
 brain structural changes, 248
 brain structure and function,
 265–269
 changes in the central
 autonomic network, 275
 characteristics, 284
 comorbidities, 275
 effects of body position, 259
 effects of sleep deprivation on
 the brain, 264
 effects of sleep fragmentation
 on the brain, 264
 effects of sleep hypoxia on the
 brain, 264–265
 effects on apolipoprotein $\epsilon 4$
 genotype, 270
 effects on blood pressure, 265
 effects on brain
 electrophysiological
 integrity, 270
 effects on brain health, 264–265
 effects on cognitive function,
 269–270
 effects on hippocampal
 neurogenesis, 270
 effects on metabolic function,
 269–270
 effects on sleep architecture, 269
 effects on synaptic integrity,
 270
 effects on vascular function,
 269
 findings from neuroimaging
 studies, 284–288
 gender risk factor, 258
 genetic risk factors, 259
 imaging of gene–environment
 interactions, 270
 imaging treatment and
 intervention effects,
 259–261
 in multiple system atrophy,
 310
 in Parkinson's disease, 310
 male–female differences, 240
 models of brain dysfunction in
 OSA, 291–292
 obesity risk factor, 258
 risk factor for dementia, 264,
 269–270
 risk factor for diabetes,
 269–270
 risk factor for secondary
 hypertension, 265
 risk factor for stroke, 265
 risk factors and exacerbators,
 258–259
 upper airway edema risk
 factor, 258–259
 upper airway involvement, 256
 OSA airway imaging
 age risk factor, 258
 airway change during
 respiration, 256–258
 airway study modalities, 256
 continuous positive airway
 pressure (CPAP), 259
 effects of body position, 259
 effects of obesity, 258
 effects of oral appliances, 260
 effects of surgical
 interventions, 260–261
 effects of weight loss, 259–260
 factors affecting airway
 collapsibility, 256–258

- gender risk factor, 258
 genetic risk factors, 259
 OSA risk factors and
 exacerbators, 258–259
 results of studies, 261
 structural and dynamic airway
 changes, 256–258
 treatment and intervention
 effects, 259–261
 upper airway anatomical
 components, 256
 upper airway edema risk
 factor, 258–259
- OSA brain structural changes
 effects of diabetes, 252
 future research directions,
 252–253
 influence of depression/
 anxiety, 251
 influences on, 251–252
 male–female differences, 240
 summary of affected brain
 regions, 252
- OSA neuroimaging
 abnormal patterns in OSA
 patients, 281
 autonomic challenge studies
 review, 280
 changes leading to autonomic
 dysfunction, 281–282
 cingulum bundle volume
 reduction, 250–251
 cortical thickness, 249
 diffusion tensor imaging (DTI)
 findings, 250
 expiratory loading, 277–278
 forehead cold pressor
 challenge, 275
 hand grip challenge, 280–281
 hippocampal volume
 reduction, 250
 inspiratory loading, 278–279
 mammillary body volume
 reduction, 250
 MRS findings, 248
 regional gray matter volume,
 248
 studies showing gray matter
 loss, 280
 Valsalva maneuver, 275–277
 visual inspection findings,
 248
 volume reduction in specific
 structures, 250–251
- OSA treatment
 continuous positive airway
 pressure (CPAP), 5, 259
 oral appliances, 260
 potential contributions from
 neuroimaging, 270–271
 surgical interventions,
 260–261
 weight loss, 259–260
- OSA treatment effects
 and models of brain
 dysfunction in OSA,
 291–292
 diffusion tensor imaging (DTI)
 of CPAP effects, 291
 functional neuroimaging of
 CPAP effects, 289–290
 limitations of imaging studies,
 292
 MRS during CPAP, 291
 near-infrared spectroscopy
 (NIRS) during CPAP,
 290–291
 neuroimaging studies,
 288–292
 structural neuroimaging of
 CPAP effects, 288–289
- OSAHS (obstructive sleep apnea-
 hypopnea syndrome)
 SPECT imaging, 51
- OSAS (obstructive sleep apnea
 syndrome), 79
- oxidative stress, 269, 270
- oxygen 15 (¹⁵O)-water
 production, 32
- oxygen 17 (¹⁷O) MRS, 26
- P300 sources, 74
- painful nocturnal erections, 302
- paired-like homeobox 2B
 (*PHOX2B*) gene defects
 congenital central
 hypoventilation syndrome
 (CCHS), 293
 effects on autonomic nervous
 system development, 293
- palinopsia in dreams, 125
- panic disorders
 brain SPECT imaging, 50
- paradoxical sleep
 features of, 8
- parahippocampal place area
 (PPA), 138, 139
- paralimbic system
 modulation of arousal,
 199–200
- paralysis, 4
- paramagnetism, 15–16
- parasomnia overlap disorder case
 study, 349
 discussion and key points, 350
 imaging findings, 350
 imaging technique, 350
 polysomnographic findings,
 349
- parasomnia overlap syndrome
 RBD/RSWA and sleepwalking,
 302
- parasomnias
 catathrenia, 304
 exploding head syndrome, 303
 hypnic headaches, 303
 limitations of imaging
 modalities, 304
- neuroimaging, 5
 neuroimaging of underlying
 pathology, 301
 nocturnal eating syndrome, 303
 sleep-related eating disorder,
 303
 sleep-related enuresis, 302
 sleep-related groaning, 304
 sleep-related hallucinations,
 303
 sleep-related headaches, 303
See also disorders of arousal,
 zolpidem-induced
 parasomnias.
- paraventricular nucleus of the
 hypothalamus, 173, 175
- parietal cortex, 92
- parietal lobe
 insomnia neuroimaging
 studies, 188, 193
- Parkinson's disease
 and idiopathic RBD, 324–325
 and substantia nigra
 hyperechogenicity, 60
 Braak staging system, 305
 brain SPECT imaging, 49
 cardiac uptake of ¹²³I-MIBG,
 333
 changes in sleep architecture,
 269
 clinical features, 305
 differential diagnosis, 49
 dopamine system dysfunction,
 306–308
 excessive daytime sleepiness
 (EDS), 309–310
 future role of neuroimaging,
 313
¹²³I-MIBG findings, 334
 imaging of dopamine
 function, 306–308
 imaging of the cholinergic
 system, 308
 incidence of sleep disorders,
 305
 neuroimaging of chemical
 pathways, 305–309
 neuroimaging of sleep
 disorders, 305
 nigrostriatal degeneration, 305
 noradrenergic system imaging,
 308–309
 OSA (obstructive sleep apnea),
 310
 pathological processes, 305
 periodic limb movement
 syndrome (PLMS), 310–311
 premotor stage, 324–325
 quality of life (QOL) rating
 scales, 305
 REM sleep behavior disorder
 (RBD), 311–313
 restless legs syndrome (RLS),
 310–311
- role of hypocretin, 309
- serotonergic system imaging,
 309
- sleep disordered breathing,
 310
- sleep rating scale (PDSS), 305
- SPECT imaging
 transcranial B-mode
 sonography (TCS), 59–60
- Parkinson's disease with
 dementia
 brain SPECT imaging, 47
- parkinsonian syndromes, 335
- ¹²³I-MIBG findings, 335
- parkinsonism
 brain SPECT imaging, 49
 drug induced, 49
See also multiple system
 atrophy.
- pedunculo-pontine tegmental
 cholinergic nuclei, 209
- perceptual load theory of
 attention, 139
- performance
 and circadian rhythms, 3
- peri-locus coeruleus α (peri-
 LC α), 9
- PERIOD3* (*PER3*) genotypes
 effects of light exposure on
 sleep, 174–175
 link to chronotypes, 165–167
 time-of-day dependent
 cognitive brain responses,
 165–167
 vulnerability to sleep loss
 effects on cognition,
 165–167
- periodic limb movement
 disorder (PLMD), 5, 355
- periodic limb movement
 syndrome (PLMS)
 in Parkinson's disease,
 310–311
- periodic limb movements
 (PLM), 59
- periodic limb movements during
 sleep (PLMS), 5, 363
 definition, 355
 in multiple system atrophy, 310
 symptoms, 355
- periodic limb movements during
 wakefulness (PLMW), 355,
 363
- peripheral perceptual processing
 capacity
 effects of sleep deprivation,
 139–140
- PET (positron emission
 tomography), 1–2, 41
 basic science, 32–36
¹¹C-labeled radiotracers, 32
 clinical principles, 37–38
 combination with CT, 31
 combination with MRI, 31

Index

- PET (positron emission tomography) (cont.)
 display/imaging, 38
¹⁸F-FDG imaging protocols, 28
 instrumentation, 32–36
 narcolepsy studies, 223
 neurological applications, 31
¹⁵O-water production, 32
 principles, 31
 production of ¹⁸F-FDG, 32
 radiopharmaceuticals
 production by cyclotron, 31–32
 PET scanners, 41
 pharmacological MRI (phMRI), 406
 pharmacotherapy
 functional neuroimaging of effects, 5–6
 phenytoin, 301
 phosphorus 31 (³¹P) MRS, 26
 photoreception system
 sensitivity to blue light, 171–172
 Pittsburgh Sleep Quality Index (PSQI), 203
 polyopia in dreams, 125
 pontine inhibitory area (PIA), 9
 pontine reticular formation, 209
 pontine waves, 114
 pontis caudalis nucleus, 9
 pontis oralis nucleus, 9
 ponto-geniculo-occipital waves, 114
 positron emission tomography.
See PET
 posterior cingulate cortex, 92
 posterior hypothalamus
 role in REM sleep control, 12
 posttraumatic stress disorder (PTSD)
 and sleep disturbances, 340–341, 342
 definition, 340
 DSM-IV-TR diagnostic criteria, 340
 neural correlates, 342–344
 polysomnography studies, 342
 prevalence, 340
 research potential of sleep neuroimaging, 344
 risk factors, 340
 sleep neuroimaging, 342–344
 symptoms, 340
 trauma exposure and sleep disturbances, 341
 treatments, 340
 pramipexole, 355
 precession of nuclei in a magnetic field, 16
 precuneus, 92
 prefrontal cortex, 210
 pregabalin, 355
 premotor cortex, 175
 preparatory attention, 141
 pretectum, 172
 prion diseases. *See* fatal familial insomnia
 prion protein (PrP) gene (*PRNP*), 375
 Probability Atlas, 74
 progressive supranuclear palsy (PSP), 49
¹²³I-MIBG findings, 335
 protease-resistant scrapie prion protein (PrP^{Sc}), 375
 proton density (MRI), 18
 protons
 behavior in a magnetic field, 15
 psychiatric disorders
 brain SPECT imaging, 50
 Psychomotor Vigilance Task (PVT), 138, 164
 psychophysiological interaction (PPI), 130
 pulsed gradient magnetic fields in MRI, 15
 pulvinar, 173, 175
 pure autonomic failure (PAF), 335
 radio frequency fields in MRI, 15
 radionuclides, 41
 radiopharmaceuticals
 production by cyclotron, 31–32
 SPECT imaging, 42–43
 raphe echogenicity, 58
 raphe hypoechogenicity
 in depressive disorders, 59
 in restless legs syndrome, 59
 rapid eye movement sleep. *See* REM sleep
 Raven's Progressive Matrices, 407
 recurrent isolated sleep paralysis, 304
 red nucleus, 57, 58
 hyperechogenicity in RLS, 59
 reduplicative paramnesia, 125
 REM sleep
 and dreaming, 125
 brain plasticity during, 116–118
 control role of the MCH neurons, 12
 control role of the posterior hypothalamus, 12
 features of, 8, 114
 mechanisms, 9–11
 mechanisms of activation of SLD PS-on neurons, 11–12
 memory processing, 116–118
 network model for onset and control, 12
 neural systems related to, 210
 neural underpinnings, 1
 preclinical evidence of neural mechanisms, 209
 relation to emotional neural systems, 213
 structures involved, 305–306
 switching mechanisms, 8
 REM sleep behavior disorder (RBD), 305
 and ¹²³I-MIBG uptake, 336
 characteristic features, 316
 clinical significance, 317–318
 idiopathic form, 316
 in multiple system atrophy, 311–313
 in Parkinson's disease, 311–313
 neuroimaging, 5
 neuroimaging findings, 329
 pathophysiology, 317–318
 SPECT imaging, 51
 transcranial B-mode sonography (TCS), 59–60
 uptake on ¹²³I-MIBG scintigraphy, 333
 with RSWA and sleepwalking, 302
 REM sleep neuroimaging, 316–317
 amygdala activation and dream content, 124
 and neural mechanisms of dreams, 119
 dream correlates, 115–116
 functional neuroanatomy, 114–115
 functional neuroimaging studies, 210
 imaging studies in depression, 210–211
 memory content of dreams, 116
 memory processing in dreams, 116
 relationship to dreams, 118–119
 REM sleep physiology, 316
 REM sleep without atonia, 302, 317–318, 333
 repetitive transcranial magnetic stimulation (rTMS), 130
 effects in sleep deprivation studies, 130, 132
 research tools
 SPECT imaging, 51
 reserpine, 334
 resting state networks, 105–106
 effects of sleep deprivation, 130
 and sleep-related epilepsies, 388
 restless legs syndrome (RLS)
 and iron deficiency, 356, 363
 and iron metabolism, 5
 and periodic limb movements during sleep (PLMS), 305, 355
 and SSRIs, 51
 augmentation problem with treatments, 363
 conventional neuroimaging (CT and MRI), 356
 course of the disorder, 363
 definition, 355
 diagnostic criteria, 363
 differential diagnosis, 59
 diffusion tensor imaging (DTI), 359–360
 dopamine system functional neuroimaging, 364–369
 dopamine system involvement, 355, 356, 363
 dopaminergic therapy, 355
 fMRI studies, 360
 functional neuroimaging, 364–369
 future neuroimaging studies, 371
 genetic factors, 356
 genome-wide association studies, 356
 in multiple system atrophy, 310
 in Parkinson's disease, 310–311
 iron neuroimaging studies, 371
 linkage studies, 356
 management, 355
 metabolism neuroimaging studies, 369–371
 neuroanatomy, 355–356
 neuroimaging, 5
 neuroimaging findings, 360–361
 neurophysiology, 356
 opiate system involvement, 363
 opioid system neuroimaging studies, 369–371
 pain neuroimaging studies, 369–371
 pathophysiology, 355–356, 363
 raphe hypoechogenicity, 59
 red nucleus hyperechogenicity, 59
 role of neuroimaging, 360–361
 substantia nigra hypoechogenicity, 59
 symptoms, 355
 transcranial B-mode sonography (TCS), 59
 treatments, 363
 voxel-based morphometry, 356–359
 restless legs syndrome (RLS) risk SPECT imaging, 51
 risky decision-making. *See* decision-making under risk
 Rolandic epilepsy, 384
 ropinirole, 355
 rotigotine, 355
 schizophrenia
 brain SPECT imaging, 50
 sleep neuroimaging, 213
 seasonal affective disorder (SAD), 171

- light therapy, 176–177
- sedating medication effects
 action of benzodiazepines, 397
 action of z-drugs, 397
 benzodiazepines, 396
 benzodiazepines (during sleep), 399–400
 benzodiazepines (wake state), 397–399
 findings from neuroimaging studies, 401–403
 functional neuroimaging during sleep, 399–401
 functional neuroimaging during wakefulness, 397–399
 GABA_A receptor modulators, 396
 GABA_A receptor role, 397
 GABA_A receptor targeting, 396–397
 melatonin, 399
 sedating antidepressants, 399
 z-drugs, 396
 z-drugs (during sleep), 400–401
 z-drugs (wake state), 399
- selective attention
 effects of sleep deprivation, 137–138
- serotonergic neurons, 8
- serotonergic system
 in multiple system atrophy, 309
 in Parkinson's disease, 309
 neuroimaging, 309
- shift workers, 177
- shrinking LORETA-FOCUSS (SLF), 75
- SIESTA project, 73
- signal-to-noise ratio (SNR), 20
 MRI, 20
- single molecule arrays, 264
- single-photon emission
 computed tomography. *See* SPECT imaging
- SISCOM (subtraction ictal SPECT coregistered with MRI), 48
- sleep
 gene expression during, 265
 sleep and memory, 179
 neuroimaging investigations, 179–180
 processes happening during sleep, 185
 reactivation during sleep, 180–182
 reorganization during sleep, 182–184
 reprocessing during sleep, 184–185
 systems memory
 consolidation, 179–180
- sleep architecture
 changes with aging, 269
 effects of OSA, 269
- sleep deprivation
 effects on brain health, 264
 in depression, 213
- sleep deprivation and decision-making, 145
 and risky decision-making, 145
 behavioral studies of decision-making, 146
 effects on risk-taking, 146–148
 increased expectation of gain, 146–148
 reduced concern for losses, 146–148
 relation to shifts in vigilance, 149–150
 relative shift in monetary valuation, 148–149
 relative shift in social valuation, 148–149
- sleep deprivation effects
 differentiation across
 behavioral measures, 159
- sleep deprivation responses
 dimensions of inter-individual differences, 154
 effects on vigilant attention, 154–155
 functional imaging of inter-individual differences, 155
 imaging predictor of individual performance, 155–157
 in clock gene *PERIOD3* (*PER3*) polymorphisms, 165–167
 influential factors, 154
 marker of inter-individual variability, 157
 shifts in activation across states, 157
 similarity to cognitive aging effects, 154–155
 vulnerability to loss of cognitive brain function, 165–167
- sleep deprivation studies
 affective aspects of behavior, 132
 attention lapses from loss of top-down control, 140–141
 BOLD imaging, 129–130
 circadian effects, 134
 default mode network (DMN), 130
 distractor suppression, 138
 effects of cognitive domain tested, 131–132
 effects of donepezil, 132
 effects of modafinil, 132
 effects of task difficulty, 131–132
 effects on decision-making, 132
 effects on selective attention, 137–138
- emotional processing, 132
 evaluating countermeasures, 132
 evaluating resting state networks, 130
 evaluation of functional connectivity, 130
 fMRI combined with EEG, 130
 fMRI combined with TMS, 130
 future functional imaging studies, 132–134
 imaging genomics, 133
 inter-individual differences, 131–132
 method for attention investigations, 137
 peripheral perceptual processing capacity, 139–140
 pioneering studies, 130
 preparatory attention, 141
 psychophysiological interaction (PPI), 130
 reduced functional circuits, 141–142
 similarities to cognitive aging, 134
 sleep fragmentation, 132–133
 sleep inertia, 134
 sleeping when awake, 141–142
 task-related fMRI, 129–130
 use of fMRI, 129
 visual short-term memory, 140
- sleep-deprived performance
 influence of default mode network, 157
 influence of subcortical areas, 157
- sleep disordered breathing, 305
 cardiovascular consequences, 5
 in multiple system atrophy, 310
 in Parkinson's disease, 310
- sleep disorders
 brain SPECT imaging, 50–51
 future directions in brain imaging, 6
 information from study of dreams, 125
 neuroimaging methods, 4
 neuroimaging of medication effects, 5–6
 range of applications for light therapy, 177
- sleep fragmentation, 132–133
 and hypertension, 265
 and insulin resistance, 264
 and metabolic syndrome, 264
 effects on brain health, 264
- sleep homeostasis, 163
 and the sleep/wake cycle, 163–164
 brain mechanisms involved in circadian interactions, 168
 effects of light on sleep regulation, 174
- sleep homeostatic mechanism, 187–188
- sleep homeostatic processes
 interaction with circadian processes, 168–169
- sleep hypoxia
 effects on the brain, 264–265
- sleep inertia, 134
- sleep loss
 effects on performance, 3
 neuroimaging of effects, 3
- sleep mechanisms
 neuroimaging technology applications, 1–2
- sleep medicine, 1, 4
 potential contributions from neuroimaging, 270–271
- sleep neuroimaging
 data interpretation challenges, 121–123
- sleep paralysis, 218
- sleep pathology
 effects on brain health, 264–265
- sleep regulation
 effects of light exposure on *PERIOD3* (*PER3*) genotypes, 174–175
 influence of light exposure, 174
- sleep-related dissociative disorder, 304
- sleep-related eating disorder, 303
- sleep-related enuresis, 302
- sleep-related epilepsies, 384
 brain networks, 387–388
 electroencephalography (EEG), 384–385
 functional MRI (fMRI), 385–386
 functional network
 connectivity analysis, 387–388
 future neuroimaging research, 388–389
 neuroimaging approaches, 384
 relationship between sleep and epilepsy, 384
 resting state networks, 387–388
 simultaneous EEG and fMRI, 385
 structural MRI, 386–387
 Wada test, 386
- sleep-related groaning (catathrenia), 304
- sleep-related hallucinations, 303
- sleep-related headaches, 303
- sleep research
 key developments, 1
- sleep spindles, 96–97
 neural correlates, 97–99
- sleep terrors
 neuroimaging, 301–302
- sleep/wake cycle
 extreme chronotypes, 164–165

Index

- sleep/wake cycle (cont.)
 PET study, 163
 sleep homeostasis, 163
 time-of-day modulations in
 cognitive performance,
 164–165
 wake maintenance zone, 163
 sleep/wake cycle regulation, 396
 brain mechanisms involved in
 circadian and homeostasis
 interactions, 168
 influence of light exposure, 171
 interaction between
 homeostatic and circadian
 processes, 163–164
 interaction of sleep
 homeostatic and circadian
 processes, 168–169
PERIOD3 (PER3) genotypes,
 165–167
 regulatory processes,
 163–164
 two-process model, 396
 sleep/wake functions
 early applications of
 neuroimaging, 2–3
 sleepwalking
 neuroimaging, 301
 with RBD/RSWA, 302
 sleepwalking case study
 case history, 347
 discussion and key points, 348
 imaging findings, 348
 imaging technique, 348
 neural correlates of
 sleepwalking, 348
 polysomnographic findings,
 347
 role of the cingulate cortex, 348
 sliding genioplasty, 260
 sLORETA (standardized low-
 resolution brain
 electromagnetic
 tomography), 74–75, 76–79
 slow waves in NREM sleep,
 96–97
 neural correlates, 99
 slow-wave sleep (SWS)
 features of, 8
 social valuation
 effects of sleep deprivation,
 148–149
 sodium oxybate, 228
 spatial regularization (S-MAP),
 75
 spatiotemporal modeling, 75
 spatiotemporal regularization
 (ST-MAP), 75
 SPECT imaging, 1–2
 AIDS dementia, 47
 Alzheimer's disease, 47
 apoptosis, 49
 applications for brain SPECT,
 45–52
 as a research tool, 51
 blood–brain barrier (BBB)
 disruption, 48
 brain death assessment, 48
 brain tumors, 48
 cadmium zinc telluride (CZT)
 technology, 41–42
 cerebral vasculitis, 48
 cerebrovascular disease, 45–46
 comparison with PET, 52
 dementia, 47
 dementia of Alzheimer's type
 (DAT), 47
 diaschisis, 46
 epilepsy, 47–48
 filtered back-projection (FBP)
 technique, 43–44
 frontal lobe dementia (FD), 47
 frontotemporal dementia, 47
 future developments, 52
 head trauma, 48
 idiopathic RBD, 51
 image interpretation, 44–45
 instrumentation, 41–42
 iterative reconstruction
 techniques, 44
 Kleine–Levin syndrome, 51
 Lewy body dementia, 47
 mechanism of brain perfusion
 imaging, 43
 median root prior (MRP)
 reconstruction algorithm, 44
 medical applications, 41
 mild cognitive impairment, 47
 ML-EM reconstruction
 algorithm, 44
 multi-infarct dementia, 47
 narcolepsy, 50–51
 narcolepsy studies, 223
 OSAHS (obstructive sleep
 apnea-hypopnea
 syndrome), 51
 OS-EM reconstruction
 algorithm, 44
 panic disorders, 50
 Parkinson's disease, 43, 49
 Parkinson's disease with
 dementia, 47
 parkinsonism, 49
 procedure for brain SPECT, 43
 psychiatric disorders, 50
 quantification, 45
 radiopharmaceuticals, 42–43
 reconstruction techniques,
 43–44
 REM sleep behavior disorder
 (RBD), 51
 restless legs syndrome risk, 51
 schizophrenia, 50
 silicon Compton camera, 42
 sleep disorders, 50–51
 stroke, 45–46, 49
 substance abuse and
 dependence, 50
 systemic lupus erythematosus
 (SLE), 48
 unipolar depression, 50
 using radiolabeled annexin
 V, 49
 vascular dementia, 47
 SPECT/CT, 51–52
 comparison with PET, 52
 future developments, 52
 spin angular momentum, 16
 spin density (MRI), 18
 spin echo (MRI), 17–18
 sporadic fatal familial insomnia,
 376
 sporadic olivopontocerebellar
 atrophy, 379
 SQUID (superconducting
 quantum interference
 device), 63
 SSRIs (selective serotonin
 reuptake inhibitors), 59, 202
 and restless legs syndrome, 51
 standardized low-resolution
 brain electromagnetic
 tomography. *See* sLORETA
 standardized shrinking
 LORETA-FOCUSS
 (SSLOFO), 75
 State-Trait Anxiety Inventory,
 234
 static magnetic field (B_0), 16
 statistical parametric mapping
 (SPM), 51
 stimulant medication effects. *See*
 alerting medication effects
 STIR image (MRI), 18
 stroke
 and sleep disordered
 breathing, 5
 brain SPECT imaging, 49
 diaschisis, 46
 hyperperfusion (hyperemia) of
 the lesion, 45
 localization using SPECT, 45
 luxury perfusion
 phenomenon, 45
 OSA risk factor, 265
 SPECT imaging, 45–46
 Stroop paradigm, 165
 subcoeruleus nucleus (SubC), 9
 subcortical areas
 influence on sleep-deprived
 performance, 157
 sublateralodorsal tegmental
 nucleus (SLD), 9–11
 activation of PS-on neurons,
 11–12
 substance abuse and dependence
 brain SPECT imaging, 50
 substantia nigra, 57
 echogenicity, 58
 hyperechogenicity, 58, 60,
 325–326
 hypoechogenicity, 58
 substantia nigra dysfunction
 and RBD, 308
 superparamagnetism, 16
 suprachiasmatic nuclei (SCN), 3,
 163, 164, 171, 173,
 175, 187
 supramarginal gyrus, 173
 Symptom Checklist 90
 (SCL-90), 234
 synaptic function and sleep, 265
 synaptic homeostasis model of
 NREM sleep, 270
 synaptic integrity
 effects of sleep disorders, 270
 synucleinopathies, 305
 autonomic failure, 336
 cardiac uptake of ^{123}I -MIBG,
 333
 systemic lupus erythematosus
 (SLE)
 brain SPECT imaging, 48
 systems memory consolidation,
 179–180
 Talairach human brain atlas, 74
 tauopathies
 ^{123}I -MIBG findings, 335
 temporal cortex, 175
 temporal lobe
 insomnia neuroimaging
 studies, 188–190
 thalamus, 173
 activation and sleep
 deprivation, 157
 role in insomnia, 200–202
 third ventricle
 width measurement, 58
 Tikhonov regularization, 73, 75
 time-of-day modulations in
 cognitive performance,
 164–165
 TOF-MRA (time-of-flight
 magnetic resonance
 angiography), 20–21
 transcranial B-mode sonography
 (TCS), 57
 application in sleep disorders,
 58–60
 depressive disorders, 59
 evaluation of structures, 58
 Parkinson's disease diagnosis,
 59–60
 REM sleep behavior disorder
 (RBD), 59–60
 restless legs syndrome (RLS),
 59
 scanning procedure, 57–58
 technical aspects, 57
 transcranial Doppler and duplex
 sonography (TCD), 57
 transcranial magnetic
 stimulation (TMS), 125
 combined with EEG, 125
 sleep deprivation studies, 130
 transcranial sonography, 1–2
 transmissible prion diseases, 375
 transpalatal advancement
 pharyngoplasty (TPAP), 260

- trauma exposure and sleep disturbances, 341
- triazolam. *See* benzodiazepines
- tuberal hypothalamus, 8
- tuberomammillary nucleus, 8
- two-process model of sleep regulation, 396
- tyrosine hydroxylase (TH)-immunoreactivity, 335
- unipolar depression
 brain SPECT imaging, 50
- upper airway edema
 risk factor for OSA, 258–259
- uvulopalatopharyngo-glossoplasty (UPPGP), 260
- uvulopalatopharyngoplasty (UPPP), 260
- Valsalva maneuver
 OSA neuroimaging, 275–277
- variable resolution electrical tomography (VARETA), 75
- vascular dementia
 brain SPECT imaging, 47
 risk factors, 269–270
- vascular function
 effects of sleep apnea, 269
- venlafaxine, 228
- venography. *See* MRA (magnetic resonance angiography)
- ventral gigantocellular nuclei (GiV), 11
- ventral striatum, 147, 148
- ventral subparaventricular zone, 187
- ventrolateral prefrontal cortex, 173, 175, 209
- ventrolateral preoptic nucleus (VLPO), 8–9
- ventromedial prefrontal cortex, 148, 199
- vesicular glutamate transporter 2 (vGlut2), 11
- vigilance, 137
 effects of sleep deprivation, 149–150
- vigilance states
 features of, 8
 switching mechanisms, 8
 types of, 8
- vigilant attention
 effects of sleep deprivation, 154–155
- visual aspects of dreams, 124
- visual distortions in dreams, 124–125
- visual short-term memory
 effects of sleep deprivation, 140
- volumetric imaging
 MRI, 20
- von Zerssen BF-S Scale, 234
- voxel-based morphometry (VBM), 218–220
- voxels, 20
- Wada test, 386
- wake maintenance zone, 163
- wakefulness
 brain activity during wakeful rest, 91
 default mode network (DMN), 92
 definition, 91
 EEG findings, 91–92
 fMRI findings, 91, 92
 neuroimaging findings in relaxed wakefulness, 93–94
 regulation of wake/sleep transitions, 91
 role of the limbic system, 91
 role of the orexin system, 91
 simultaneous EEG and fMRI findings, 93
- wakefulness neuroimaging
 compared with NREM sleep, 96
- waking state
 features of, 8
 mechanisms involved, 8
 switch to NREM sleep, 9
- weight loss
 effects on OSA, 259–260
- weighted minimum norm estimates (WMNE), 75
- weighted resolution optimization (WROP), 75
- white matter tracts
 diffusion tensor imaging (DTI), 24–26
- whole-brain voxel-based morphometry (VBM), 189
- Wilson's disease
 features of, 391
 incidence of sleep abnormalities, 391
 MRI findings, 393
 patient description, 391
- polysomnography, 392–393
 questionnaires-based
 assessment, 391–392
 sleep profile, 391–393
 Wisconsin Card Sorting Task, 407
- X-rays
 use in computed tomography (CT), 15
- Yoga Nidra, 201
- z-drugs, 396
 and GABA_A receptors, 397
 effects during sleep, 400–401
 neuroimaging of effects, 399
See also eszopiclone, zaleplon, zolpidem, zopiclone.
- zaleplon, 396
See also z-drugs.
- zolpidem, 396
 effects during sleep, 400–401
 effects during wakefulness, 399
 effects in patients with neurological disorders, 401
 side effects, 301
See also z-drugs.
- zolpidem-induced parasomnias
 discussion and key points, 415
 imaging findings, 415
 imaging technique, 415
 mode of action of zolpidem, 415
 patient history, 414
- zopiclone, 396
See also z-drugs.